Keeping you up to dateLatest Clearstate Healthcare Insights postsClearstate Insights is your single source to all our latest healthcare intelligence. From recently published reports offering thought-provoking analysis, to information about new products and services, we will ensure you are always kept informed. Sign up to Clearstate’s newsletter
Middle East IVD market to recover to pre-pandemic growth rates from 2024 The Middle East IVD market has mostly recovered to… Centralised Diagnostics (CEDx) | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Middle East & Africa | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT)
Q2 2022 IVD China: point-of-care infectious-disease testing outperforms during the latest covid surge The impact of China’s latest covid-19 surge heads the… Centralised Diagnostics (CEDx) | Covid-19 testing | In-vitro diagnostics | Infectious Diseases Testing Monitor | Molecular Diagnostics (MDx) | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx)
Outside of covid-19 diagnostics: Nine out of 16 APAC IVD markets have recovered to pre-pandemic levels Asia-Pacific (APAC) IVD markets have grown and exceeded… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | Infectious Diseases Testing Monitor | IVD Gateway | Molecular Diagnostics (MDx)
Most common cancer biomarkers for Europe NGS testing: RAS, BRAF, EGFR Most-commonly tested cancer biomarkers using NGS in Europe… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Larger gene panels are the predominant NGS testing strategy in EU5 Larger gene panels are the predominant NGS testing strategy… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Europe: precision medicine and access to NGS cancer biomarker testing Precision medicine and access to NGS cancer biomarker… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019 Proportion of cancer biomarker testing done with NGS… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Insights into Europe’s covid-19 testing and technology use 2021-2022: PCR v serology v antigen Europe is shifting its covid-19-approach from pandemic to… Centralised Diagnostics (CEDx) | Covid-19 testing | In-vitro diagnostics | Molecular Diagnostics (MDx) | Europe | IVD Gateway | Molecular Diagnostics (MDx)
Ageing and the Impact on Japan’s IVD Market In this report “Ageing and the Impact on Japan’s IVD… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Asia | IVD Gateway
Brazil IVD market: Zooming in on high-growth segments As the largest in vitro diagnostic (IVD) market in Latin… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Americas | IVD Gateway
China IVD market: Driving the next leg of growth In this whitepaper “China IVD Market 2019: Driving the… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Asia | IVD Gateway
Sign up to our free newsletterThe latest trends and insights into the IVD and Surgical sectors, from our specialists and analysts, delivered directly to your inbox. Sign up to Clearstate’s newsletter today. Sign up now